Decades of studies of candidate genes show their complex role in aging-related traits. We focus on apolipoprotein E e2/3/4 polymorphism and ages at onset of cardiovascular diseases (CVD) and cancer in the parental and offspring generations of the Framingham Heart Study participants to gain insights on the role of age and gender across generations in genetic trade-offs. The analyses show that the apolipoprotein E e4 allele carriers live longer lives without cancer than the non-e4 allele carriers in each generation. The role of the e4 allele in onset of CVD is age- and generation-specific, constituting two modes of sexually dimorphic genetic trade-offs. In offspring, the e4 allele confers risk of CVD primarily in women and can protect against cancer primarily in men of the same age. In the parental generation, genetic trade-off is seen in different age groups, with a protective role of the e4 allele against cancer in older men and its detrimental role in CVD in younger women. The puzzling complexity of genetic mechanisms working in different genders, ages, and environments calls for more detail and systemic analyses beyond those adapted in current large-scale genetic association studies.
Get full access to this article
View all access options for this article.
References
1.
FinchCE, TanziRE. Genetics of aging. Science, 1997; 278:407–411.
2.
MartinGM. Modalities of gene action predicted by the classical evolutionary biological theory of aging. Ann NY Acad Sci, 2007; 1100:14–20.
StrangerBE, StahlEA, RajT. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics, 2011; 187:367–383.
5.
WilliamsGC. Pleiotropy, natural selection, and the evolution of senescence. Evolution, 1957; 11:398–411.
6.
WilliamsPD, DayT. Antagonistic pleiotropy, mortality source interactions, and the evolutionary theory of senescence. Evolution, 2003; 57:1478–1488.
7.
KulminskiAM, CulminskayaI, UkraintsevaSV, ArbeevKG, LandKC, YashinAI. Beta2-adrenergic receptor gene polymorphisms as systemic determinants of healthy aging in an evolutionary context. Mech Ageing Dev, 2010; 131:338–345.
8.
SummersK, CrespiBJ. Xmrks the spot: Life history tradeoffs, sexual selection and the evolutionary ecology of oncogenesis. Mol Ecol, 2010; 19:3022–3024.
9.
AlexanderDM, WilliamsLM, GattJM, Dobson-StoneC, KuanSA, ToddEG, SchofieldPR, CooperNJ, GordonE. The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. Biol Psychol, 2007; 75:229–238.
De BenedictisG, CarotenutoL, CarrieriG, De LucaM, FalconeE, RoseG, YashinAI, BonafeM, FranceschiC. Age-related changes of the 3′ APOB-VNTR genotype pool in ageing cohorts. Ann Hum Genet, 1998; 62,Pt 2:115–122.
12.
IlveskoskiE, PerolaM, LehtimakiT, LaippalaP, SavolainenV, PajarinenJ, PenttilaA, LaluKH, MannikkoA, LiestoKK, KoivulaT, KarhunenPJ. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: An autopsy study. Circulation, 1999; 100:608–613.
13.
YashinAI, UkraintsevaSV, De BenedictisG, AnisimovVN, ButovAA, ArbeevK, JdanovDA, BoikoSI, BegunAS, BonafeM, FranceschiC. Have the oldest old adults ever been frail in the past? A hypothesis that explains modern trends in survival. J Gerontol A Biol Sci Med Sci, 2001; 56:B432–B442.
14.
JarvikGP, GoodeEL, AustinMA, AuwerxJ, DeebS, SchellenbergGD, ReedT. Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: A longitudinal analysis. Am J Hum Genet, 1997; 61:171–181.
15.
BergmanA, AtzmonG, YeK, MacCarthyT, BarzilaiN. Buffering mechanisms in aging: A systems approach toward uncovering the genetic component of aging. PLoS Comput Biol, 2007; 3:e170.
16.
KulminskiAM, UkraintsevaSV, ArbeevKG, MantonKG, OshimaJ, MartinGM, Il'yasovaD, YashinAI. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. J Am Geriatr Soc, 2008; 56:478–483.
17.
KulminskiAM, CulminskayaI, UkraintsevaSV, ArbeevKG, ArbeevaL, WuD, AkushevichI, LandKC, YashinAI. Trade-off in the effects of the apolipoprotein E polymorphism on the ages at onset of CVD and cancer influences human lifespan. Aging Cell, 2011; 10:533–541.
18.
CrespiBJ. The origins and evolution of genetic disease risk in modern humans. Ann NY Acad Sci, 2010; 1206:80–109.
19.
KulminskiAM, CulminskayaIV, UkraintsevaSV, ArbeevKG, AkushevichI, LandKC, YashinAI. Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: The case of myocardial infarction. Rejuvenation Res, 2010; 13:13–21.
20.
WangK, BaldassanoR, ZhangH, QuHQ, ImielinskiM, KugathasanS, AnneseV, DubinskyM, RotterJI, RussellRK, BradfieldJP, SleimanPM, GlessnerJT, WaltersT, HouC, KimC, FrackeltonEC, GarrisM, DoranJ, RomanoC, CatassiC, Van LimbergenJ, GutherySL, DensonL, PiccoliD, SilverbergMS, StanleyCA, MonosD, WilsonDC, GriffithsA, GrantSF, SatsangiJ, PolychronakosC, HakonarsonH. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Hum Mol Genet, 2010; 19:2059–2067.
21.
BarnesJA, DixDJ, CollinsBW, LuftC, AllenJW. Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress Chaperones, 2001; 6:316–325.
22.
UkraintsevaSV, ArbeevKG, AkushevichI, KulminskiA, ArbeevaL, CulminskayaI, AkushevichL, YashinAI. Trade-offs between cancer and other diseases: Do they exist and influence longevity?Rejuvenation Res, 2010; 13:387–396.
23.
WeilbachFX, ToykaKV. Does Down's syndrome protect against multiple sclerosis?Eur Neurol, 2002; 47:52–55.
24.
FinchCE. Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: Roles of infection, inflammation, and nutrition. Proc Natl Acad Sci USA, 2010; 107,Suppl 1:1718–1724.
25.
CharlesworthB. Evolution of senescence: Alzheimer's disease and evolution. Curr Biol, 1996; 6:20–22.
26.
MartinGM. APOE alleles and lipophylic pathogens. Neurobiol Aging, 1999; 20:441–443.
27.
FrazerKA, MurraySS, SchorkNJ, TopolEJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet, 2009; 10:241–251.
28.
van HeemstD, MooijaartSP, BeekmanM, SchreuderJ, de CraenAJ, BrandtBW, SlagboomPE, WestendorpRG. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol, 2005; 40:11–15.
29.
DentonK, BaylisC. Physiological and molecular mechanisms governing sexual dimorphism of kidney, cardiac, and vascular function. Am J Physiol Regul Integr Comp Physiol, 2007; 292:R697–R699.
30.
NedungadiTP, CleggDJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res, 2009; 2:321–327.
31.
DawberTR. The Framingham study: The Epidemiology of Atherosclerotic Disease. Harvard University Press: Cambridge, MA, 1980.
32.
GailMH, JohnsonNL. Proceedings of the American Statistical Association: sesquicentennial invited papers session. American Statistical Association, Alexandria, VA, 1989.
33.
GovindarajuDR, CupplesLA, KannelWB, O'DonnellCJ, AtwoodLD, D'AgostinoRBSr., FoxCS, LarsonM, LevyD, MurabitoJ, VasanRS, SplanskyGL, WolfPA, BenjaminEJ. Genetics of the Framingham Heart Study population. Adv Genet, 2008; 62:33–65.
34.
SplanskyGL, CoreyD, YangQ, AtwoodLD, CupplesLA, BenjaminEJ, D'AgostinoRBSr., FoxCS, LarsonMG, MurabitoJM, O'DonnellCJ, VasanRS, WolfPA, LevyD. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, recruitment, and initial examination. Am J Epidemiol, 2007; 165:1328–1335.
35.
CupplesLA, Heard-CostaN, LeeM, AtwoodLD. Genetics Analysis Workshop 16 Problem 2: The Framingham Heart Study data. BMC Proc, 2009; 3,Suppl 7:S3.
36.
LahozC, SchaeferEJ, CupplesLA, WilsonPW, LevyD, OsgoodD, ParposS, Pedro-BotetJ, DalyJA, OrdovasJM. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis, 2001; 154:529–537.
37.
MyersRH, SchaeferEJ, WilsonPW, D'AgostinoR, OrdovasJM, EspinoA, AuR, WhiteRF, KnoefelJE, CobbJL, McNultyKA, BeiserA, WolfPA. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology, 1996; 46:673–677.
38.
LeeEW, WeiLJ, AmatoDA, LeurgansS. Cox-type regression-analysis for large numbers of small-groups of correlated failure time observations. Nato Adv Sci I E-App., 1992; 211:237–247.
39.
KulminskiAM, CulminskayaI, ArbeevKG, UkraintsevaSV, StallardE, ArbeevaL, YashinAI. The role of lipid-related genes, aging-related processes, and environment in healthspan. 2012.
40.
KolovouG, DamaskosD, AnagnostopoulouK, CokkinosDV. Apolipoprotein E gene polymorphism and gender. Ann Clin Lab Sci, 2009; 39:120–133.
41.
HirashikiA, YamadaY, MuraseY, SuzukiY, KataokaH, MorimotoY, TajikaT, MuroharaT, YokotaM. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol, 2003; 42:1429–1437.
42.
ScuteriA, BosAJ, ZondermanAB, BrantLJ, LakattaEG, FlegJL. Is the apoE4 allele an independent predictor of coronary events?Am J Med, 2001; 110:28–32.
43.
Frikke-SchmidtR, Tybjaerg-HansenA, SteffensenR, JensenG, NordestgaardBG. Apolipoprotein E genotype: Epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: The Copenhagen City Heart Study. J Am Coll Cardiol, 2000; 35:1192–1199.
44.
de JongPT. Age-related macular degeneration. N Engl J Med, 2006; 355:1474–1485.
Tabares-SeisdedosR, DumontN, BaudotA, ValderasJM, ClimentJ, ValenciaA, Crespo-FacorroB, VietaE, Gomez-BeneytoM, MartinezS, RubensteinJL. No paradox, no progress: Inverse cancer comorbidity in people with other complex diseases. Lancet Oncol, 2011; 12:604–608.
47.
ChasmanDI, KozlowskiP, ZeeRY, KwiatkowskiDJ, RidkerPM. Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun, 2006; 7:211–219.
48.
NikiteasNI, TzanakisN, GazouliM, RallisG, DaniilidisK, TheodoropoulosG, KostakisA, PerosG. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: Prognostic implications. World J Gastroenterol, 2005; 11:1639–1643.
49.
KoukourakisMI, KambouromitiG, PitsiavaD, TsousouP, TsiarkatsiM, KartalisG. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation, 2009; 32:169–175.
50.
OrdovasJM. Gender, a significant factor in the cross talk between genes, environment, and health. Gend Med, 2007; 4,Suppl B:S111–S122.
51.
EichnerJE, DunnST, PerveenG, ThompsonDM, StewartKE, StroehlaBC. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol, 2002; 155:487–495.
52.
NeelJV, WederAB, JuliusS. Type II diabetes, essential hypertension, and obesity as “syndromes of impaired genetic homeostasis”: The “thrifty genotype” hypothesis enters the 21st century. Perspect Biol Med, 1998; 42:44–74.
53.
KuningasM, MooijaartSP, van HeemstD, ZwaanBJ, SlagboomPE, WestendorpRG. Genes encoding longevity: From model organisms to humans. Aging Cell, 2008; 7:270–280.
54.
VijgJ, SuhY. Genetics of longevity and aging. Annu Rev Med, 2005; 56:193–212.
55.
BoomsmaDI, KempenHJ, Gevers LeuvenJA, HavekesL, de KnijffP, FrantsRR. Genetic analysis of sex and generation differences in plasma lipid, lipoprotein, and apolipoprotein levels in adolescent twins and their parents. Genet Epidemiol, 1996; 13:49–60.
56.
EichlerEE, FlintJ, GibsonG, KongA, LealSM, MooreJH, NadeauJH. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet, 2010; 11:446–450.
57.
GibsonG. Decanalization and the origin of complex disease. Nat Rev Genet, 2009; 10:134–140.
58.
MacRaeCA, VasanRS. Next-generation genome-wide association studies: Time to focus on phenotype?Circ Cardiovasc Genet, 2011; 4:334–336.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
